Silk Road Medical, Inc Share Price

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 12:50:00 01/05/2024 am IST 5-day change 1st Jan Change
19.6 USD +3.73% Intraday chart for Silk Road Medical, Inc +10.24% +58.76%
Sales 2024 * 196M 16.33B Sales 2025 * 217M 18.1B Capitalization 745M 62.21B
Net income 2024 * -54M -4.51B Net income 2025 * -50M -4.17B EV / Sales 2024 * 3.76 x
Net cash position 2024 * 9.23M 770M Net cash position 2025 * 38.77M 3.24B EV / Sales 2025 * 3.26 x
P/E ratio 2024 *
-13.8 x
P/E ratio 2025 *
-14.9 x
Employees 474
Yield 2024 *
0.68%
Yield 2025 *
-
Free-Float 93.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.73%
1 week+10.24%
Current month+6.33%
1 month+10.49%
3 months+28.24%
6 months+170.56%
Current year+58.76%
More quotes
1 week
16.40
Extreme 16.4
19.61
1 month
16.40
Extreme 16.4
19.61
Current year
11.05
Extreme 11.05
22.52
1 year
6.08
Extreme 6.08
45.02
3 years
6.08
Extreme 6.08
67.49
5 years
6.08
Extreme 6.08
75.80
10 years
6.08
Extreme 6.08
75.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 02/11
Director of Finance/CFO 46 01/09/01
Chief Tech/Sci/R&D Officer - 21/20/21
Members of the board TitleAgeSince
Director/Board Member 56 26/18/26
Director/Board Member 51 03/20/03
Chairman 70 01/07/01
More insiders
Date Price Change Volume
01/24/01 19.48 +3.10% 331 611
29/24/29 18.9 +6.18% 417,504
26/24/26 17.8 +0.85% 449,136
25/24/25 17.65 +0.46% 621,585
24/24/24 17.57 -0.57% 607,675

Delayed Quote Nasdaq, April 01, 2024 at 12:34 am IST

More quotes
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
18.9 USD
Average target price
18.43 USD
Spread / Average Target
-2.49%
Consensus